Oxyresveratrol from Artocarpus lakoocha Roxb. Inhibit Melanogenesis in B16 Melanoma Cells through the Role of Cellular Oxidants

Teerapat RODBOON; Pranom PUCHADAPIROM; Seiji OKADA; Prasit SUWANNALERT

Authors

Teerapat RODBOON Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok 10400
Pranom PUCHADAPIROM Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok 10400
Seiji OKADA Division of Hematopoiesis, Center for AIDS Research, Kumamoto University, Kumamoto 860-0811
Prasit SUWANNALERT Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok 10400

Keywords:

Oxyresveratrol, melanin, tyrosinase, oxidative stress, melanoma cell

Abstract

Overproduction of melanin pigment is well recognized in hyperpigmentation disorders and melanoma progression. In this study, we investigated the anti-oxidant activity of oxyresveratrol from Artocarpus lakoocha Roxb. The effects of oxyresveratrol on melanogenesis, tyrosinase activity, and cellular oxidants in B16 cells were also obtained. Toxic doses of oxyresveratrol were confirmed by using an in vitro micronucleus method in V79 cells. Oxyresveratrol had a potent anti-oxidant activity. It also showed a statistical significance in the inhibition of melanogenesis, tyrosinase activity, and cellular oxidants in B16 cells at 10 and 12.5 mg/ml. These effective doses had no toxicity in V79 cells. Oxyresveratrol had a potent inhibition of melanogenesis in B16 cells through the role of cellular oxidants relating to tyrosinase activity. Effective doses of this agent may be used to control hyperpigmentation disorders and to be applied in chemopreventive drugs for melanoma.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biography

Prasit SUWANNALERT, Department of Pathobiology, Faculty of Science, Mahidol University, Bangkok 10400

Department of Pathobiology

References

R Sarangarajan and SP Apte. Melanin aggregation and polymerization: Possible implications in age-related macular degeneration. Ophthalmic Res. 2005; 37, 136-41.

TS Chang. An updated review of tyrosinase inhibitors. Int. J. Mol. Sci. 2009; 10, 2440-75.

MMC Grierson and AD Ormerod. Nitric oxide function in the skin. Nitric Oxide 2004; 10; 179-93.

Y Son, YK Cheong, NH Kim, HT Chung, DG Kang and HO Pae. Mitogen-activated protein kinases and reactive oxygen species: How can ROS activate MAPK pathways? J. Signal Transduct. 2011; 2011, 792639.

JJ Yohn, DA Norris, DG Yrastorza, IJ Buno, JA Leff, SS Hake and JE Repine. Disparate antioxidant enzyme activities in cultured human cutaneous fibroblasts, keratinocytes, and melanocytes. J. Invest. Dermatol. 1991; 97, 405-9.

SL Church, JW Grant, LA Ridnour, LW Oberley, PE Swanson, PS Meltzer and JM Trent. Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells. Proc. Natl. Acad. Sci. USA 1993; 90, 3113-7.

S Yang, K Irani, SE Heffron, F Jurnak and FL Meyskens. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 2005; 4, 1923-35.

YJ Kim. Antimelanogenic and antioxidant properties of gallic acid. Biol. Pharm. Bull. 2007; 30, 1052-5.

T Yokozawa and YJ Kim. Piceatannol inhibits melanogenesis by its antioxidative actions. Biol. Pharm. Bull. 2007; 30, 2007-11.

YJ Kim and H Uyama. Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future. Cell. Mol. Life Sci. 2005; 62, 1707-23.

S Maneechai, K Likhitwitayawuid, B Sritularak, C Palanuvej, N Ruangrungsi and P Sirisa-ard. Quantitative analysis of oxyresveratrol content in Artocarpus lakoocha and ‘Puag-Haad’. Med. Princ. Pract. 2009; 18, 223-7.

JK Kim, M Kim, SG Cho, MK Kim, SW Kim and YH Lim. Biotransformation of mulberroside A from Morus alba results in enhancement of tyrosinase inhibition. J. Ind. Microbiol. Biotechnol. 2010; 37, 631-7.

P Lorenz, S Roychowdhury, M Engelmann, G Wolf and TFW Horn. Oxyresveratrol and resveratrol are potent antioxidants and free radical scavengers: Effect on nitrosative and oxidative stress derived from microglial cells. Nitric Oxide 2003; 9, 64-76.

AJ Stratigos and AD Katsambas. Optimal management of recalcitrant disorders of hyperpigmentation in dark-skinned patients. Am. J. Clin. Dermatol. 2004; 5, 161-8.

ML Bilodeau, JD Greulich, RL Hullinger, C Bertolotto, R Ballotti and OM Andrisani. BMP-2 stimulates tyrosinase gene expression and melanogenesis in differentiated melanocytes. Pigment Cell Res. 2001; 14, 328-36.

F Hu and RR Cardell. The ultrastructure of pigmented melanoma cells in continuous culture. J. Invest. Dermatol. 1964; 42, 67-79.

VC Lin, HY Ding, SY Kuo, LW Chin, JY Wu and TS Chang. Evaluation of in vitro and in vivo depigmenting activity of raspberry ketone from rheum officinale. Int. J. Mol. Sci. 2011; 12, 4819-35.

U Panich, T Onkoksoong, S Limsaengurai, P Akarasereenont and A Wongkajornsilp. UVA-induced melanogenesis and modulation of glutathione redox system in different melanoma cell lines: The protective effect of gallic acid. J. Photochem. Photobiol. B 2012; 108, 16-22.

A Seelbach, B Fissler, A Strohbusch and S Madle. Development of a modified micronucleus assay in vitro for detection of aneugenic effects. Toxicol. In Vitro 1993; 7, 185-93.

M Delijewski, D Wrześniok, M Otręba, A Beberok, J Rok and E Buszman. Nicotine impact on melanogenesis and antioxidant defense system in HEMn-DP melanocytes. Mol. Cell. Biochem. 2014; 395, 109-16.

P Suwannalert, R Kariya, I Suzu and S Okada. The effects of Salacia reticulata on anti-cellular oxidants and melanogenesis inhibition in alpha-MSH-stimulated and UV irradiated B16 melanoma cells. Nat. Prod. Commun. 2014; 9, 551-4.

T Yokozawa and YJ Kim. Piceatannol inhibits melanogenesis by its antioxidative actions. Biol. Pharm. Bull. 2007; 30, 2007-11.

YJ Kim and H Uyama. Tyrosinase inhibitors from natural and synthetic sources: structure, inhibition mechanism and perspective for the future. Cell. Mol. Life Sci. 2005; 62, 1707-23.

A Khemis, A Kaiafa, C Queille-Roussel, L Duteil and JP Ortonne. Evaluation of efficacy and safety of rucinol serum in patients with melasma: A randomized controlled trial. Br. J. Dermatol. 2007; 156; 997-1004.

U Panich, V Tangsupa-a-nan, T Onkoksoong, K Kongtaphan, K Kasetsinsombat, P Akarasereenont and A Wongkajornsilp. Inhibition of UVA-mediated melanogenesis by ascorbic acid through modulation of antioxidant defense and nitric oxide system. Arch. Pharm. Res. 2011; 34, 811-20.

SJ Lee, SW Cho, YY Kwon, HS Kwon and WC Shin. Inhibitory effects of ethanol extracts from nuruk on oxidative stress, melanogenesis, and photo-aging. Mycobiology 2012; 40; 117-23.

K Watanabe, S Shibuya, Y Ozawa, H Nojiri, N Izuo, K Yokote and T Shimizu. Superoxide dismutase 1 loss disturbs intracellular redox signaling, resulting in global age-related pathological changes. Biomed. Res. Int. 2014; 2014, 1-10.

S Yang, K Irani, SE Heffron, F Jurnak and FL Meyskens. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther. 2005; 4, 1923-35.

S Yang, BJ Misner, RJ Chiu and FL Meyskens. Redox effector factor-1, combined with reactive oxygen species, plays an important role in the transformation of JB6 cells. Carcinogenesis 2007; 28, 2382-90.